Unknown

Dataset Information

0

Effective and targeted latency reversal in CD4+ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection.

ABSTRACT: To date, an affordable, effective treatment for an HIV-1 cure remains only a concept with most "latency reversal" agents (LRAs) lacking specificity for the latent HIV-1 reservoir and failing in early clinical trials. We assessed HIV-1 latency reversal using a multivalent HIV-1-derived virus-like particle (HLP) to treat samples from 32 people living with HIV-1 (PLWH) in Uganda, US and Canada who initiated combined antiretroviral therapy (cART) during chronic infection. Even after 5-20 years on stable cART, HLP could target CD4+ T cells harbouring latent HIV-1 reservoir resulting in 100-fold more HIV-1 release into culture supernatant than by common recall antigens, and 1000-fold more than by chemotherapeutic LRAs. HLP induced release of a divergent and replication-competent HIV-1 population from PLWH on cART. These findings suggest HLP provides a targeted approach to reactivate the majority of latent HIV-1 proviruses among individuals infected with HIV-1.

SUBMITTER: Ngo MH 

PROVIDER: S-EPMC10967673 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

To date, an affordable, effective treatment for an HIV-1 cure remains only a concept with most "latency reversal" agents (LRAs) lacking specificity for the latent HIV-1 reservoir and failing in early clinical trials. We assessed HIV-1 latency reversal using a multivalent HIV-1-derived virus-like particle (HLP) to treat samples from 32 people living with HIV-1 (PLWH) in Uganda, US and Canada who initiated combined antiretroviral therapy (cART) during chronic infection. Even after 5-20 years on st  ...[more]

Similar Datasets

Unknown PD-1 blockade potentiates HIV latency reversal ex vivo in CD4<sup>+</sup> T cells from ART-suppressed individuals.
| S-EPMC6379401 | biostudies-literature
Unknown Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
| S-EPMC4024870 | biostudies-literature
Unknown Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4<sup>+</sup> T cell activation and HIV-1 latency reversal.
| S-EPMC6436934 | biostudies-literature
Unknown Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy.
| S-EPMC6943937 | biostudies-literature
Transcriptomics HIV latency reversal via combined non-canonical NF- B agonism and targeted BET family bromodomain inhibition
2022-02-10 | GSE196091 | GEO
Unknown HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro: implications for latency reversal.
| S-EPMC6319264 | biostudies-literature
Unknown Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.
| S-EPMC4920395 | biostudies-literature
Unknown Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
| S-EPMC6715238 | biostudies-literature
Unknown Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy.
| S-EPMC9014398 | biostudies-literature
Unknown Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4<sup>+</sup> T Cells.
| S-EPMC6103814 | biostudies-literature